Alasdair Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alasdair Taylor has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Colin Neil Alexander Palmer
University of Dundee
3 shared publications Carolina Haefliger
Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
2 shared publicationsJavier Armisen
Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca PLC, Cambridge, UK
2 shared publicationsMoneeza K Siddiqui
Population Health and Genomics, University of Dundee, Dundee, UK
2 shared publicationsPhilip Ambery
Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca PLC, Gothenburg, Sweden
2 shared publications- Adem Y. Dawed
Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK
1 shared publication
Latest Publications
- Open Access
Common and rare variants in SLCO1B1 are associated with statin intolerance
Background and Aims: The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1 , which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, will provide more reliable estimates of statin intolerance. Methods and Results: High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: OR GSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy OR SRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: OR SRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (OR Val174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; OR risk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HR Val174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HR risk-haplotypes 2.44 [95%CI:1.46, 4.08],pSLCO1B1 , in addition to Val174Ala, provides more reliable estimates of statin intolerance.
Open AccessCommon and rare variants in SLCO1B1 are associated with statin intolerance
Background and Aims: The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1 , which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, will provide more reliable estimates of statin intolerance. Methods and Results: High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: OR GSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy OR SRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: OR SRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (OR Val174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; OR risk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HR Val174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HR risk-haplotypes 2.44 [95%CI:1.46, 4.08],pSLCO1B1 , in addition to Val174Ala, provides more reliable estimates of statin intolerance.
- Open Access
- 25 March 2022
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 9 (1) , e000817
Metabolic dysfunction-related liver disease as a risk factor for cancer
Objective: The aim of this study was to investigate the association between obesity, diabetes and metabolic related liver dysfunction and the incidence of cancer. Design: This study was conducted with health record data available from the National Health Service in Tayside and Fife. Genetics of Diabetes Audit and Research Tayside, Scotland (GoDARTS), Scottish Health Research Register (SHARE) and Tayside and Fife diabetics, three Scottish cohorts of 13 695, 62 438 and 16 312 patients, respectively, were analysed in this study. Participants in GoDARTS were a volunteer sample, with half having type 2 diabetes mellitus(T2DM). SHARE was a volunteer sample. Tayside and Fife diabetics was a population-level cohort. Metabolic dysfunction-related liver disease (MDLD) was defined using alanine transaminase measurements, and individuals with alternative causes of liver disease (alcohol abuse, viruses, etc) were excluded from the analysis. Results: MDLD associated with increased cancer incidence with a HR of 1.31 in a Cox proportional hazards model adjusted for sex, type 2 diabetes, body mass index(BMI), and smoking status (95% CI 1.27 to 1.35, p − 2). BMI was not independently associated with cancer incidence when MDLD was included as a covariate. Conclusion: MDLD, FLI, FIB-4 and NASH associated with increased risk of cancer incidence and death. NAFLD may be a major component of the relationship between obesity and cancer incidence.
- 25 March 2022
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 9 (1) , e000817
Open AccessMetabolic dysfunction-related liver disease as a risk factor for cancer
Objective: The aim of this study was to investigate the association between obesity, diabetes and metabolic related liver dysfunction and the incidence of cancer. Design: This study was conducted with health record data available from the National Health Service in Tayside and Fife. Genetics of Diabetes Audit and Research Tayside, Scotland (GoDARTS), Scottish Health Research Register (SHARE) and Tayside and Fife diabetics, three Scottish cohorts of 13 695, 62 438 and 16 312 patients, respectively, were analysed in this study. Participants in GoDARTS were a volunteer sample, with half having type 2 diabetes mellitus(T2DM). SHARE was a volunteer sample. Tayside and Fife diabetics was a population-level cohort. Metabolic dysfunction-related liver disease (MDLD) was defined using alanine transaminase measurements, and individuals with alternative causes of liver disease (alcohol abuse, viruses, etc) were excluded from the analysis. Results: MDLD associated with increased cancer incidence with a HR of 1.31 in a Cox proportional hazards model adjusted for sex, type 2 diabetes, body mass index(BMI), and smoking status (95% CI 1.27 to 1.35, p − 2). BMI was not independently associated with cancer incidence when MDLD was included as a covariate. Conclusion: MDLD, FLI, FIB-4 and NASH associated with increased risk of cancer incidence and death. NAFLD may be a major component of the relationship between obesity and cancer incidence.
- Open Access
Metabolic Dysfunction Related Liver Disease as a Risk Factor for Cancer
The aim of this study was to investigate the association with obesity, diabetes and related liver dysfunction and the incidence of cancer. This study was conducted with health record data available from the National Health Service in Tayside and Fife. GoDARTS, SHARE and Tayside and Fife diabetics, three Scottish cohorts of 13,695, 62,438, and 16,312 patients respectively were analysed in this study. Participants in GoDARTS were a volunteer sample, with half having T2DM. SHARE were a volunteer sample. Tayside and Fife diabetics was a population level cohort. Metabolic dysfunction-related liver disease (MDLD) was defined using ALT measurements, and individuals with alternative causes of liver disease (alcohol abuse, viruses etc) were excluded from the analysis. Other indicators of liver disease were analysed including the Fatty Liver Index, Fibrosis Score(FIB-4) and hospital admissions for NASH. The main outcomes were cancer incidence and cancer death. MDLD associated with increased cancer incidence with a hazard ratio of 1.31 in a cox proportional hazards model adjusted for sex, type 2 diabetes, BMI, and smoking status (95% CI = 1.27 – 1.35, p < 0.0001). This was replicated in two further cohorts, and similar associations with cancer incidence were found for Fatty Liver Index (FLI), FIB-4 and NASH. Homozygous carriers of the common NAFLD risk variant PNPLA3 rs738409 had increased risk of cancer. (HR = 1.27 (1.02-1.58), p = 3.1×10 −2 ). BMI was not independently associated with cancer incidence when MDLD was included as a covariate. MDLD was associated with increased risk of cancer death (HR = 1.40, 95% CI =1.33 - 1.47, p < 0.0001). MDLD, FLI, FIB-4 and NASH associated with increased risk of cancer incidence and death. Further, we found evidence of a causal association between NAFLD and cancer using the established causal risk allele of PNPLA3 as a genetic instrument. NAFLD may be a major component of the relationship between obesity and cancer incidence. Lay Summary: We found that individuals with metabolic dysfunction-related liver disease (MDLD) have higher overall cancer risk than healthy individuals, as well as increased risk of specific cancers such as colon, breast and lung. We also show that when MDLD is accounted for, obesity does not significantly increase overall cancer risk.
Open AccessMetabolic Dysfunction Related Liver Disease as a Risk Factor for Cancer
The aim of this study was to investigate the association with obesity, diabetes and related liver dysfunction and the incidence of cancer. This study was conducted with health record data available from the National Health Service in Tayside and Fife. GoDARTS, SHARE and Tayside and Fife diabetics, three Scottish cohorts of 13,695, 62,438, and 16,312 patients respectively were analysed in this study. Participants in GoDARTS were a volunteer sample, with half having T2DM. SHARE were a volunteer sample. Tayside and Fife diabetics was a population level cohort. Metabolic dysfunction-related liver disease (MDLD) was defined using ALT measurements, and individuals with alternative causes of liver disease (alcohol abuse, viruses etc) were excluded from the analysis. Other indicators of liver disease were analysed including the Fatty Liver Index, Fibrosis Score(FIB-4) and hospital admissions for NASH. The main outcomes were cancer incidence and cancer death. MDLD associated with increased cancer incidence with a hazard ratio of 1.31 in a cox proportional hazards model adjusted for sex, type 2 diabetes, BMI, and smoking status (95% CI = 1.27 – 1.35, p < 0.0001). This was replicated in two further cohorts, and similar associations with cancer incidence were found for Fatty Liver Index (FLI), FIB-4 and NASH. Homozygous carriers of the common NAFLD risk variant PNPLA3 rs738409 had increased risk of cancer. (HR = 1.27 (1.02-1.58), p = 3.1×10 −2 ). BMI was not independently associated with cancer incidence when MDLD was included as a covariate. MDLD was associated with increased risk of cancer death (HR = 1.40, 95% CI =1.33 - 1.47, p < 0.0001). MDLD, FLI, FIB-4 and NASH associated with increased risk of cancer incidence and death. Further, we found evidence of a causal association between NAFLD and cancer using the established causal risk allele of PNPLA3 as a genetic instrument. NAFLD may be a major component of the relationship between obesity and cancer incidence. Lay Summary: We found that individuals with metabolic dysfunction-related liver disease (MDLD) have higher overall cancer risk than healthy individuals, as well as increased risk of specific cancers such as colon, breast and lung. We also show that when MDLD is accounted for, obesity does not significantly increase overall cancer risk.